SpringWorks Therapeutics Expands Portfolio with Precision Medicine Approach and Shared-Value Partnerships

Strategic Insights -

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that has successfully expanded its portfolio with a precision medicine approach and strategic partnerships. The company's differentiated portfolio of small molecule targeted oncology product candidates has enabled it to advance two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Key Takeaways:

  • The company has a portfolio of small molecule targeted oncology product candidates, including nirogacestat and mirdametinib, which are being developed for the treatment of desmoid tumors and neurofibromatosis type 1-associated plexiform neurofibromas, respectively.
  • SpringWorks Therapeutics has obtained Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation for nirogacestat from the FDA, and Orphan Drug Designation for mirdametinib from the FDA.
  • The company has initiated a potentially registrational Phase 3 clinical trial of nirogacestat for adult patients with desmoid tumors and a Phase 2 clinical trial of nirogacestat for pediatric patients with desmoid tumors.
  • SpringWorks Therapeutics is expanding its portfolio through shared-value partnerships with industry leaders, including GlaxoSmithKline, Janssen Biotech, Inc., Pfizer, Allogene Therapeutics, Inc., Precision BioSciences, Inc., and Seagen Inc.
  • The company has also in-licensed the TEA Domain, or TEAD, inhibitor program from Katholieke Universiteit Leuven, or KU Leuven, and the Flanders Institute for Biotechnology, or VIB.

Statistics:

  • The company has a differentiated portfolio of small molecule targeted oncology product candidates.
  • SpringWorks Therapeutics has obtained a total of 13 orphan drugs designations from the FDA and European Commission.
  • The company has one potentially registrational Phase 3 clinical trial and one Phase 2 clinical trial ongoing.
  • SpringWorks Therapeutics has partnered with 7 industry leaders to develop novel combination regimens of nirogacestat.

Sources:

  • SpringWorks Therapeutics, Inc. (2021, February 25). Annual Report on Form 10-K for the year ended December 31, 2020.
  • SpringWorks Therapeutics, Inc. (2021, May 9). Management's Discussion and Analysis of Financial Condition and Results of Operations.
  • SpringWorks Therapeutics, Inc. (2021, July 14). DeFi trial press release.